Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

详细信息    查看全文

• 作者：Jean-Philippe Spano ; Catherine Chodkiewicz ; Joan Maurel ; Ralph Wong ; Harpreet Wasan ; Carlo Barone ; Richard Lé ; tourneau ; Emilio Bajetta ; Yazdi Pithavala ; Paul Bycott ; Peter Trask ; Katherine Liau ; A
• 关键词：Fast food ; Young adult ; Adolescent ; Longitudinal study
• 刊名：The Lancet
• 出版年：2008
• 出版时间：21 June 2008-27 June 2008
• 年：2008
• 卷：371
• 期：9630
• 页码：2101-2108
• 全文大小：190 K

文摘

Axitinib (AG-013736) is a potent and selective oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, which have an important role in pancreatic cancer. The aim of this study was to assess the safety and efficacy of gemcitabine plus axitinib versus gemcitabine alone.